Brian Abrahams
Stock Analyst at RBC Capital
(2.21)
# 2,790
Out of 5,120 analysts
441
Total ratings
44.49%
Success rate
-6.11%
Average return
Main Sectors:
Stocks Rated by Brian Abrahams
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $14 → $13 | $6.66 | +95.20% | 20 | Jan 30, 2026 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $28 → $30 | $17.09 | +75.54% | 1 | Jan 29, 2026 | |
| GHRS GH Research | Maintains: Outperform | $33 → $40 | $15.94 | +150.94% | 2 | Jan 23, 2026 | |
| DFTX Definium Therapeutics | Maintains: Outperform | $20 → $36 | $18.04 | +99.56% | 1 | Jan 23, 2026 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | $455 → $546 | $465.88 | +17.20% | 57 | Jan 22, 2026 | |
| APGE Apogee Therapeutics | Downgrades: Sector Perform | $70 → $83 | $66.54 | +24.74% | 3 | Jan 22, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $70 → $103 | $77.76 | +32.46% | 2 | Dec 16, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $160 → $180 | $139.46 | +29.07% | 24 | Dec 8, 2025 | |
| SION Sionna Therapeutics | Downgrades: Underperform | $24 | $43.35 | -44.64% | 2 | Dec 1, 2025 | |
| PTCT PTC Therapeutics | Downgrades: Sector Perform | $82 → $91 | $76.00 | +19.74% | 23 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $7 | $2.01 | +249.13% | 7 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $22 | $14.96 | +47.06% | 6 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $13.36 | +34.73% | 5 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $53 | $8.29 | +539.32% | 9 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $1.5 → $1 | $0.99 | +1.03% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $10 → $11 | $8.92 | +23.32% | 12 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $3 → $2 | $1.22 | +63.93% | 14 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $28 → $32 | $34.50 | -7.25% | 13 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $32 | $25.11 | +27.44% | 3 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $58 | $41.90 | +38.44% | 20 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $19 | $6.39 | +197.57% | 13 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $105 | $145.25 | -27.71% | 34 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $217 → $210 | $178.77 | +17.47% | 41 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $704 → $708 | $760.82 | -6.94% | 34 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $81 → $84 | $102.87 | -18.34% | 24 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $67 → $10 | $16.02 | -37.58% | 3 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $23 | $20.66 | +11.33% | 35 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $1.5 | $0.11 | +1,327.21% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $84 | $16.74 | +401.79% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $139 → $143 | $188.95 | -24.32% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $31.60 | +26.58% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $15 | $13.59 | +10.42% | 14 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $9 | $3.89 | +131.36% | 3 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $25.15 | - | 4 | Dec 4, 2017 |
BioCryst Pharmaceuticals
Jan 30, 2026
Maintains: Outperform
Price Target: $14 → $13
Current: $6.66
Upside: +95.20%
Nurix Therapeutics
Jan 29, 2026
Maintains: Outperform
Price Target: $28 → $30
Current: $17.09
Upside: +75.54%
GH Research
Jan 23, 2026
Maintains: Outperform
Price Target: $33 → $40
Current: $15.94
Upside: +150.94%
Definium Therapeutics
Jan 23, 2026
Maintains: Outperform
Price Target: $20 → $36
Current: $18.04
Upside: +99.56%
Vertex Pharmaceuticals
Jan 22, 2026
Upgrades: Outperform
Price Target: $455 → $546
Current: $465.88
Upside: +17.20%
Apogee Therapeutics
Jan 22, 2026
Downgrades: Sector Perform
Price Target: $70 → $83
Current: $66.54
Upside: +24.74%
Kymera Therapeutics
Dec 16, 2025
Maintains: Outperform
Price Target: $70 → $103
Current: $77.76
Upside: +32.46%
Neurocrine Biosciences
Dec 8, 2025
Maintains: Outperform
Price Target: $160 → $180
Current: $139.46
Upside: +29.07%
Sionna Therapeutics
Dec 1, 2025
Downgrades: Underperform
Price Target: $24
Current: $43.35
Upside: -44.64%
PTC Therapeutics
Dec 1, 2025
Downgrades: Sector Perform
Price Target: $82 → $91
Current: $76.00
Upside: +19.74%
Dec 1, 2025
Upgrades: Outperform
Price Target: $4 → $7
Current: $2.01
Upside: +249.13%
Nov 21, 2025
Maintains: Outperform
Price Target: $25 → $22
Current: $14.96
Upside: +47.06%
Nov 14, 2025
Maintains: Outperform
Price Target: $19 → $18
Current: $13.36
Upside: +34.73%
Nov 13, 2025
Maintains: Outperform
Price Target: $55 → $53
Current: $8.29
Upside: +539.32%
Nov 7, 2025
Maintains: Sector Perform
Price Target: $1.5 → $1
Current: $0.99
Upside: +1.03%
Nov 7, 2025
Maintains: Sector Perform
Price Target: $10 → $11
Current: $8.92
Upside: +23.32%
Nov 7, 2025
Maintains: Sector Perform
Price Target: $3 → $2
Current: $1.22
Upside: +63.93%
Nov 7, 2025
Maintains: Sector Perform
Price Target: $28 → $32
Current: $34.50
Upside: -7.25%
Nov 6, 2025
Maintains: Outperform
Price Target: $34 → $32
Current: $25.11
Upside: +27.44%
Nov 4, 2025
Maintains: Outperform
Price Target: $55 → $58
Current: $41.90
Upside: +38.44%
Nov 4, 2025
Maintains: Outperform
Price Target: $30 → $19
Current: $6.39
Upside: +197.57%
Oct 31, 2025
Maintains: Sector Perform
Price Target: $100 → $105
Current: $145.25
Upside: -27.71%
Oct 31, 2025
Maintains: Outperform
Price Target: $217 → $210
Current: $178.77
Upside: +17.47%
Oct 29, 2025
Maintains: Sector Perform
Price Target: $704 → $708
Current: $760.82
Upside: -6.94%
Oct 29, 2025
Maintains: Sector Perform
Price Target: $81 → $84
Current: $102.87
Upside: -18.34%
Sep 29, 2025
Downgrades: Sector Perform
Price Target: $67 → $10
Current: $16.02
Upside: -37.58%
Jul 17, 2025
Maintains: Sector Perform
Price Target: $25 → $23
Current: $20.66
Upside: +11.33%
May 14, 2025
Reiterates: Sector Perform
Price Target: $1.5
Current: $0.11
Upside: +1,327.21%
Apr 22, 2025
Reiterates: Outperform
Price Target: $84
Current: $16.74
Upside: +401.79%
Feb 3, 2025
Maintains: Outperform
Price Target: $139 → $143
Current: $188.95
Upside: -24.32%
Jan 28, 2025
Reiterates: Outperform
Price Target: $40
Current: $31.60
Upside: +26.58%
Oct 2, 2023
Maintains: Sector Perform
Price Target: $25 → $15
Current: $13.59
Upside: +10.42%
Mar 31, 2022
Maintains: Sector Perform
Price Target: $12 → $9
Current: $3.89
Upside: +131.36%
Dec 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $25.15
Upside: -